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a  b  s  t  r  a  c  t
15-Hydroxyprostaglandin  dehydrogenase  (HPGD)  plays  a key  role  in  prostaglandins  (PGs) catabolism.  Its
expression  and  activity  appear  to  be regulated  by progesterone  (P4).  We  investigated  the HPGD  mRNA-
expression  and  protein  localization  in  placentomes  and  interplacental  uterine  sites  throughout  gestation
(Study  I), and  after fetal  membranes  retention  (RFM)  compared  with  normally  delivered  fetal  membranes
(DFM)  (Study  II). Furthermore,  we  analyzed  the  inﬂuence  of aglepristone  (AP), dexamethasone  (GC)  or
cloprostenol  (CP),  on HPGD  expression  in  bovine  placentomes  (Study  III). Tissues  from  late gestation
(D272)  and  at normal  term (NT)  served  as  controls.  HPGD  was  highest  in  all  sites  at the  beginning  of
pregnancy  and  at (NT).  Following  induced  parturition  HPGD  was  lower  after  (AP)  and  (GC)  compared
with  (NT),  and  was  similar  in  RFM  and  DFM.  Placentomes  stained  primarily  in fetal  compartments;  inter-
placentomal  signals  were  observed  in endometrial  glandular  and  luminal  epithelium.  Results  indicate
that  HPGD  may  play a role  during  establishment  and  termination  of gestation.
©  2016  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
In ruminants, prostaglandin (PG) E2 (PGE2) and PGF2 are key
factors involved in important processes in the female reproduc-
tive system, including ovulation and luteolysis [1–3], implantation
and maintenance of pregnancy [4], induction of parturition, ripen-
ing and softening of the cervix, involution of the uterus [5,6], and
likely also in the release of fetal membranes [7]. In cattle, cortisol,
which is synthesized and secreted by the fetus, induces parturition
by increasing placental estrogen production, which leads to inten-
siﬁed production of PGF2 and thus decreasing progesterone (P4)
secretion [3,8]. Increased myometrial contractions and softening
of the birth canal parallel these events. As reviewed elsewhere in
detail [9,10], the prepartum luteolytic cascade is largely controlled
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by the activity of cyclooxygenases (COX or PTGS), in particular by its
inducible form, i.e., COX2 (PTGS2). Prostaglandins are synthesized
from membrane-bound phospholipids via utilization of phospho-
lipase A2-derived arachidonic acid (AA) as a substrate for COX [9].
PGH2 is the ﬁrst product in this pathway, which is subsequently
converted to either PGD2, PGE2 or PGF2 due to the activity of
PGD-synthase (PGDS), PGE2-synthase (PTGES) or PGF2-synthase
(PGFS), respectively [9]. Additionally, PGF2 can result from the
activity of 9-ketoprostaglandin reductase (9K-PGR) utilizing PGE2
for its synthesis, or from the reduction of PGD2 by 11-ketoreductase
[10].
Type 1 NAD+-dependent 15-hydroxyprostaglandin dehydroge-
nase (HPGD) is the key enzyme regulating the bioavailability of
PGs. It controls their activities by catalyzing the reversible oxidation
of PGs into the biologically inactive forms 13,14-dihydro-15-keto-
PGF2 (PGFM) and 13,14-dihydro-15-keto PGE2 (PGEM) [11,12].
There is strong evidence that HPGD activity is maintained by P4
[13,14] and inhibited by progesterone receptor blockers [15,16]
and glucocorticoids [17,18]. The complex regulatory mechanisms
underlying these changes remain, however, not fully understood.
Although there are several studies on HPGD expression [19–21],
regulation [22,23] and function [12,24], its expression and cellu-
lar localization have never been investigated comprehensively in
http://dx.doi.org/10.1016/j.prostaglandins.2016.12.003
1098-8823/© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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uterine and placentomal tissues during different stages of bovine
pregnancy. Furthermore, the potential role of HPGD in controlling
the maintenance of pregnancy and the induction of parturition in
cattle is poorly understood. In several previous studies, hormones
such as the glucocorticoid dexamethasone and the PGF2 analog
cloprostenol, as well as compounds interfering with P4 function,
e.g.,  the selective progesterone-receptor (PGR) blocker aglepris-
tone, have been widely tested on the induction of parturition in
ruminants [25–28] and other species like dogs [29–31] and humans
[14,18]. Their effects on diminishing plasma P4 concentrations and,
thereby, their luteolytic potential, were investigated [28,32–35].
Additional effects of using aglepristone in cows, besides shorten-
ing the gestation length, include lowered myometrial activity and
reduced softening of the birth canal compared to naturally calv-
ing cows [36]. The probability of retention of fetal membranes is
higher in cows in which parturition is induced with hormonal med-
ication [37,38]. Dexamethasone is proven to upregulate COX2 and
CYP17A1 (17alpha-hydroxylase-C17, 20-lyase) in the cotyledonary
trophoblast [36], which results in activation of the delta-5 pathway
of placental steroid biosynthesis [39]. This leads to decreased P4
synthesis in favor of estrogens. However, the roles of aglepristone,
cloprostenol and dexamethasone in regulating HPGD and, thereby,
availability of PG in the complex preterm signal cascade in cattle
are still not fully understood. Therefore, in order to characterize
their effects on maternal HPGD expression levels, and thereby the
potential involvement of HPGD in the prepartum endocrine cas-
cade in cows, preterm animals were treated with the P4 receptor
blocker aglepristone (withdrawal of both placental and luteal P4
effects), the glucocorticoid dexamethasone (mimicking the prepar-
tal increase in fetal cortisol), or the PGF2 analog cloprostenol
(induction of luteolysis). Furthermore, bovine uteri and placen-
tomes were collected from different stages of pregnancy and mRNA
expression and immunohistochemical localization of HPGD were
examined to shed new light on PG metabolism and the coordination
of pathways leading to parturition in cattle.
2. Methods
2.1. Animals
All animal experiments were conducted in accordance with
animal welfare legislation. Details about the experimental groups
and studies, and the animal experiment permissions are shown in
Table 1.
Study I included interplacentomal specimens and placentomes
of 35 Holstein-Friesian cows at different stages of pregnancy
(3rd to 9th months), which were collected at a slaughterhouse
within 30 min  after slaughtering [40,41] (n ≥ 3 animals/month of
pregnancy). The gestational age was estimated according to fetal
crown-rump length as described elsewhere [40,41]. In this study
tissue material was also included from spontaneously calving cows
of the university dairy herd at the Hannover School of Veteri-
nary Medicine Foundation, Hannover, Germany, which released the
secundinae within 12 h after expulsion of the fetus (discharged fetal
membranes; DFM; n = 5).
In Study II, DFM placentomal specimens were used and the
mRNA levels of HPDG were compared with those expressed in
patient cows undergoing routine cesarean section at the clinic
of the Hannover School of Veterinary Medicine Foundation, but
retaining the fetal membranes for more than 12 h (RFM; n = 5).
In DFM cows, placentomes were collected per vaginam within
one h after expulsion of the fetus using an elongated effeminator
according to Richter, as modiﬁed by Reisinger (Hauptner, Solin-
gen, Germany) [40]. In RFM patient cows, surgeries were performed
under local anesthesia with Procaine (Isocaine, 2% solution, Selec-
tavet, Weyarn, DE), 40 ml  paravertebral and 80 ml  at the site of the
incision, and a single placentome was  collected per animal [41].
For Study III, placentomal specimens were collected from ani-
mals following preterm cesarean section at day 272, and at induced
parturition and normal parturition. All these cows were of the
Holstein-Friesian breed with a physiological singleton pregnancy.
More speciﬁcally, as described by Shenavai et al. [32,36], elec-
tive cesarian sections were performed in untreated cows pre-term
on day 272 (D272; n = 3) after insemination and placentomes were
collected to examine the clinical situation directly before the ﬁnal
labor-inducing signals occur, but on the same day when the treated
cows were expected to deliver their calves [32,36]. Furthermore,
pregnant cows were treated on day 270 after artiﬁcial insemination
with 3 g (∼5 mg/kg of body weight) of the PGR blocker aglepristone
(AP; Alizine Virbac Bad Oldesloe, DE; n = 3; withdrawal of placen-
tal and luteal P4 effects) in 100 ml  solvent s.c. at four different
sites of the lower thoracic wall. The same procedure was repeated
24 h later on the contralateral side of the thorax. The cows treated
with glucocorticoid (GC; n = 4; mimicking the prepartal increase
in fetal cortisol) received 25 mg  dexamethasone-21-undecanoate
(Devamed
®
; Topkim, Istanbul, TR), and the cows treated with
prostaglandin (CP; n = 3; induction of luteolysis) received 150 g
D-cloprostenol (Dalmazin
®
; Selectavet Dr. Otto Fischer GmbH,
Weyarn-Holzolling, DE) on day 270 after artiﬁcial insemination
[36]. All cows were observed every 2 h for signs of impending labor.
Immediately after expulsion of calves, placentomes were collected
per vaginam. Additionally, placentomes from spontaneously calv-
ing (d280.5 ± 1.3) cows (normal term = NT; n = 5) were removed per
vaginam immediately after the expulsion of healthy calves. Secun-
dinae were released in a timely manner in these animals [36].
2.2. Tissue sampling and processing
As described by Boos et al. [41], for Study I at least two  randomly
selected and comparatively large placentomes and two  segments
of the interplacentomal uterine wall including adherent allan-
tochorion were collected at the slaughterhouse from randomly
selected cows at different stages of pregnancy. Macroscopically vis-
ible caruncles were excised with the adherent allantochorion and
the surrounding uterine wall. In DFM and RFM groups, only a sin-
gle placentome was collected from each experimental or inpatient
cow. For Study III, three to ﬁve placentomes – but no uterine wall
segments – were collected per vaginam immediately after parturi-
tion from each cow.
As described by Sprekeler et al. [42], for Study I and II the pla-
centomes were then divided into pieces of 10 × 10 mm and three
samples per placentome were selected for further processing as
follows: (1) uterine wall oriented tissue cube, i.e.,  placental tissue
including maternal plate and material of the placentomal stalk; (2)
allantoic sac oriented tissue cube, i.e.,  placental tissue including
fetal plate material, and ﬁnally (3) tissue cube collected from the
equatorial periphery also including fetal plate and placental tissue.
The samples were embedded in Tissue-Tek II (Miles, Elkhart, IN,
USA) and attached onto cork lamellae, snap frozen in liquid nitro-
gen and stored at −80 ◦C [42]. For immunohistochemistry (IHC),
besides collecting the interplacental uterine parts, the connective
fetal tissues were dissected from the placentomes directly after
collection and centrally located cross-sections of about 5 mm  in
thickness were prepared [42]. Tissue samples were then ﬁxed in
4% neutral buffered formaldehyde for 24 h, washed in tap water,
dehydrated in a graded ethanol series and acetic acid-n-butyl ester,
and ﬁnally embedded in parafﬁn as previously described [41].
For Study III, placentomes were placed on ice and rinsed in 4 ◦C
cold PBS buffer, divided into cross-sections of approximately 5 mm
thickness and ﬁxed in 4% neutral buffered formaldehyde and pro-
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Table  1
Experimental groups.
Study Description Number of cows Animal experiment permissions
I and II 3rd–9th month of gestation
Uterine and placentomal tissues; collected at
slaughterhouse
n ≥ 3 per month Animal experiments were approved by the administration
of the district Hannover, and performed according to the
German Law for the Protection of Animals (TierschG) and
the recommendations of the German Society of Laboratory
Animal Science (GV-SOLAS).
DFM: Uterine and placentomal tissues of spontaneously
calving cows with discharged fetal membranes <12 h after
the expulsion of the calf; samples collected within one
hour after expulsion of the calf
5
RFM: Placentomes of spontaneously calving cows with
retained fetal membranes >12 h; samples collected within
one hour after expulsion of the calf
5
III  AP: Placentomes of cows, which were treated with
aglepristone (AP) on day 270 after artiﬁcial insemination.
Samples collected immediately after calving.
3 Animal experiments were approved by the local ethical
committees on the use of animals for research purposes at
the regional council (Regierungspräsidium Giessen, no.
V54-19c-20-15(l) Gi 18/14-Nr.41/2007; LAVES,
33.0-42502-04-09/1634; Ethical Committee of Uludag
University of Veterinary Medicine, No.
401/1510-26.03.2007).
CP:  Placentomes of cows treated with cloprostenol
(PGF2,  Cl) on day 270 after artiﬁcial insemination.
Samples collected immediately after parturition
3
GC: Placentomes of cows treated with dexamethasone
(GC) on day 270 after artiﬁcial insemination. Samples
collected immediately after parturition
4
NT: Placentomes of spontaneously calving cows without
medical treatment; normal term (NT)
5
D272: Placentomes of untreated cows with Cesarian
section (CS) on day 272 after insemination. Samples
collected during CS
3
cessed further as described above. No frozen material was available
for this study.
2.3. RNA isolation and semi-quantitative real-time (TaqMan) PCR
Total RNA was isolated from collected placentomal and/or
uterine tissues used for Studies I and II using TRIZOL-Reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. For Study III, RNA-isolation was  performed on
formalin-ﬁxed, parafﬁn-embedded (FFPE) tissue samples using
the RNeasy FFPE-Kit (Qiagen, Valencia, CA, USA) following the
manufacturer’s protocols and as previously described [43,44]. The
RNA content and quality were measured by spectrophotome-
try (NanoDrop 2000C; Thermo Fisher Scientiﬁc AG, Reinach, CH).
DNAse treatment was accomplished with RQ1 RNAse-free DNAse
(Promega, Dübendorf, CH) following the manufacturer’s instruc-
tions in order to remove genomic DNA contaminants using 100 ng
(Studies I and II) or 400 ng (Study III) of total RNA for each sam-
ple. Reverse transcription was performed with the GOLD RNA PCR
Core Kit (Gene Amp, Applied Biosystems, Foster City, CA, USA) and
carried out in an Eppendorf Mastercycler (Vaudaux-Eppendorf AG,
Basel, CH) using an established running protocol (8 min  at 21 ◦C,
15 min  at 45 ◦C followed by 5 min  at 99 ◦C).
Semi-quantitative real-time (TaqMan) PCR of HPGD and the two
housekeeping genes SDHA and GAPDH [45] (for accession num-
bers and primer sequences see Table 2) was performed using the
automated ﬂuorometer ABI PRISM 7500 Fast Real Time PCR sys-
tem (Applied Biosystems, Rotkreuz, CH) as described previously
[40,46]. The samples were quantiﬁed in duplicate using the Fast
Start Universal Probe Master (ROX; Roche Diagnostics Schweiz
AG) on 96-well optical plates (Applied Biosystems), with cDNA
corresponding to 100 ng or 400 ng of total RNA per sample that
was DNAse-treated and synthesized as described above. Nega-
tive controls consisted of autoclaved water (instead of cDNA) and
the so-called RT minus controls (samples which were not reverse
transcribed). The reaction mixture of 25 l included 12.5 l Fast-
Start Universal Probe Master (Roche Diagnostics, Mannheim, DE),
150 nM of the forward and 150 nM of the reverse primers, 200 nM
TaqMan probe and 5 l cDNA. Primers and 6-carboxyﬂuorescein
(6-FAM)- and 6-carboxytetramethyl-rhodamine (TAMRA)-labeled
probes (Table 1) were designed with GenScript Inc. Software (Pis-
cataway, NJ, USA) and ordered from Microsynth AG, Balgach, CH.
The ampliﬁcation reaction was conducted under the following con-
ditions: denaturation at 95 ◦C for 10 min, 40 cycles at 95 ◦C for 15 s
and 60 ◦C for 60 s. The two reference genes (SDHA and GAPDH)
were used to calculate the relative gene expression of HPGD using
the comparative CT method ( CT method) in compliance with
the manufacturer’s instructions for the ABI 7500 Fast Real-Time
PCR System as described by Kowalewski et al. [47,48]. Accordingly,
the CT slope method was  applied to check the efﬁciency of the PCR
reactions that were set up to ensure approximately 100%. The speci-
ﬁcity of the selected PCR products for each gene was conﬁrmed by
commercial sequencing (Microsynth AG).
2.4. Immunohistochemical (IHC) analysis
For IHC localization of HPGD protein in bovine tissues, sections
of 3 m thickness were cut from formalin-ﬁxed and parafﬁn-
embedded samples and mounted on SuperFrost Plus microscope
slides (Menzel-Gläser, Braunschweig, DE). The sections were
deparafﬁnized in xylol, rehydrated through a graded ethanol
series and rinsed in tap water as previously described [42,49].
Antigen retrieval was performed in 10 mM citrate buffer pH 6.0
and endogenous peroxidase activity was quenched by 0.3% H2O2
in methanol. Subsequent to a wash in IHC buffer/0.3% Triton
X, (0.8 mM Na2HPO4, 1.47 mM KH2PO4, 2.68 mM KCl, 137 mM
NaCl) pH 7.2–7.4, the slides were treated with 10% normal
goat serum to block non-speciﬁc binding sites. Afterwards, the
sections were incubated with polyclonal, afﬁnity puriﬁed, custom-
made guinea pig anti-canine HPGD antibody (Eurogentec S.A.,
Seraing, BE; [49]) overnight at 4 ◦C at a dilution of 1:1000. This
antibody was  designed by using the canine peptide sequence
HFQDYETTPFHAKTQ – C – terminal amino acids 252–266 of the
HPGD sequence [GenBank:AFF60303] displaying 86% homology
with the bovine sequence. For negative and isotype controls, the
primary antibody was  replaced by IHC buffer/0.3% Triton X, or by
using pre-immune guinea pig serum matching the protein con-
centration of the antiserum, respectively. On the next day, the
sections were washed with [IHC/0.3% Triton X] and incubated with
a biotinylated secondary goat anti-guinea pig antibody (AI-7000;
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Table  2
Sequences of primers and (TaqMan) probes.
Primer Primer sequence Accession  Product length (bp)
HPGD forward 5′-GAA TCT CGA AGC AGG TGT CA-3′
HPGD reverse 5′-CCA GCT TTC CAA AGT GGT CT-3′ NM 001034419.2 106
HPGD  probe 5′-TGA TCG GCC ACA TCG CAC TG-3′
SDHA forward 5′-ATG GAA GGT CTC TGC GCT AT-3′
SDHA reverse 5′-ATG GAC CCG TTC TTC TAT GC-3′ NM 174178 79
SDHA  probe 5′-ACA GAG CGA TCA CAC CGC GG-3′
GAPDH forward 5′-GCG ATA CTC ACT CTT CTA CCT TCG A-3′
GAPDH reverse 5′-TCG TAC CAG GAA ATG AGC TTG AC-3′ NM 001034034.1 92
GAPDH probe 5′-CTG GCA TTG CCC TCA ACG ACC ACT T-3′
Vector Laboratories, Burlingame, USA) at 1:100 dilution at room
temperature for 1 h. After repeated rinsing in IHC/0.3% Triton X,
tissue slides were treated with the streptavidin-avidin-peroxidase
Vectastain ABC kit (Vector Laboratories) to enhance the signals.
For ﬁnal detection of signals, the Liquid DAB+ substrate kit (Dako
Schweiz AG, Baar, CH) was added and the reaction was  stopped after
approximately 10 min. The tissue sections were rinsed for 10 min  in
tap water, counterstained with hematoxylin, dehydrated through
serial ethanol dilutions and coverslipped mechanically in Pertex®
(RCM 2000
®
; Medite, Dietlikon, CH).
2.5. Statistics
For statistical tests the software program GraphPad Prism 5.0
(GraphPad Software Inc., San Diego, CA, USA) was used.
The datasets of semi-quantitative real-time PCR were tested
for normality using the Kolmogorov-Smirnov Test. The results of
HPGD mRNA expression in placentomes from Studies II and III
were normally distributed and therefore the datasets were tested
by a parametric one-way analysis of variance (ANOVA) followed
by Dunn‘s multiple comparison test. The remaining datasets for
the uterine and placentomal HPGD mRNA expression during dif-
ferent stages of gestation (Study I) did not show normality, so a
non-parametric one-way analysis of variance (Kruskal-Wallis test)
followed by Dunn’s post-test was applied. The numerical data are
presented as the mean ± SD. In all cases p < 0.05 was  considered as
statistically signiﬁcant.
3. Results
3.1. Expression of HPGD mRNA
Study I: stages of pregnancy
HPGD expression in uterine and placentomal tissues was
investigated by semi-quantitative real-time (TaqMan) PCR. HPGD-
speciﬁc mRNA was detected in all preparations between the 3rd
and 9th month of gestation and post-partum. Despite high indi-
vidual variations, in placentomes the highest mRNA expression of
HPGD was observed immediately post-partum (DFM), compared
with the 6th to 9th month of pregnancy (p < 0.05) (Fig. 1A).
HPGD mRNA expression in the bovine uterine wall was  signiﬁ-
cantly higher in the 3rd compared with the 6th month of pregnancy
(p < 0.05) (Fig. 1B).
Study II: DFM versus RFM.
The mRNA expression of HPGD did not differ signiﬁcantly
between the two groups (p > 0.05) (Fig. 1C).
Study III: NT, D272, CP, AP and GC
The treatments used in this study had different effects on
placentomal HPGD mRNA expression. Thus, its levels were sig-
niﬁcantly lower in cows treated with aglepristone (AP) and
dexamethasone (GC) compared with untreated cows at normal
term (NT). Placentomes of cows during late gestation (D272)
Fig. 1. Placentomal and uterine mRNA expression of HPGD at different stages of
gestation and at term. In placentomes and uteri, HPGD was  detected in all RNA
preparations between the 3rd and 9th months of pregnancy and at term, with
changes that were time-dependent. The highest mRNA expression was found during
establishment and termination of gestation. Thus, (A) placental HPGD expression
during pregnancy was signiﬁcantly higher immediately post partum (DFM) com-
pared to month 6 till 9 of pregnancy (p < 0.05). (B) uterine HPGD expression during
gestation was in the 3rd month signiﬁcantly higher than in the 6th month (p < 0.05).
The  datasets showed no normality, therefore a non-parametric one-way analysis
of  variance (Kruskal-Wallis) followed by Dunn‘s post-test was applied. (C) No sig-
niﬁcant differences were detected between cows with (DFM) or without (RFM)
discharged fetal membranes (p > 0.05). The datasets of group DFM and RFM were
normally distributed and one-way ANOVA was  applied followed by Dunn‘s multiple
comparison test. Numerical data are presented as means ± SD.
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Fig. 2. Placentomal expression proﬁle of bovine HPGD mRNA in groups NT, D272,
CP, AP and GC. Detection of signiﬁcantly lower placentomal HPGD mRNA levels
in  groups medicated with aglepristone (AP) or dexamethasone (GC) (*) compared
with untreated cows at normal term (NT) (**). P-values: NT: AP = p < 0.001; NT:
GC = p < 0.01; NT: D272 = p > 0.05; NT: CP = p > 0.05. Measured by real-time PCR (Taq-
man). Data were normally distributed and analyzed using one-way ANOVA followed
by  Dunn‘s multiple comparison test. Numerical data are presented as the mean ± SD.
and of cows treated with cloprostenol (CP) showed no signiﬁ-
cant differences in HPGD mRNA expression compared to controls
(NT). In detail: NT vs.  AP = p < 0.001; NT vs.  GC = p < 0.01; NT vs.
D272 = p > 0.05; NT vs.  CP = p > 0.05, Fig. 2.
3.2. Localization of HPGD protein
Placentomal tissues
In all placentomes, staining was clearly detected in the tro-
phoblast and the epithelium covering the maternal part of the
placentomes (caruncle), with staining intensity appearing stronger
in the trophoblast compared to the caruncular epithelium. No
considerable differences of staining were found in relation to
the localization of HPGD within the placentomal villous tree
(PVT; fetal side) or the caruncular crypt system (Fig. 3A, C–H). In
the trophoblast, immunostaining was present in uninucleate tro-
phoblast cells (UNC), but not in binucleate trophoblast cells (BNC)
(Fig. 3D–H). No staining was detected in maternal and fetal stroma
(Fig. 3C–E). The staining intensity appeared strongest during post
partum while it seemed weaker in the middle of pregnancy (Fig. 3A,
D, H). In all groups, the localization pattern of HPGD remained con-
stant (Fig. 3A–H). In some of the tissue samples, nuclear staining
was detected, which was interpreted as non-speciﬁc background
staining.
Uterine tissues
HPGD immunoreactivity was mainly localized in the endome-
trial glandular (GE) and luminal epithelium (Fig. 4A–D). The
staining appeared weaker in the stroma and in the myometrial
smooth muscle cells (MM  = myometrium) (Fig. 4B). Immunostain-
ing seemed to be more intense in the 3rd month of gestation (Fig. 4A
and B) especially when compared to the 6th month of gestation
(Fig. 4C and D) where it appeared weaker. The localization pat-
tern remained constant throughout pregnancy and at post partum
(Fig. 4A and D).
4. Discussion
The aim of the present study was to examine the expres-
sion, and thereby indirectly, the potential involvement of HPGD
in the endocrine prepartum events in cattle, and in particular
in the regulation of PGs release during bovine pregnancy and
parturition. The three different treatments intervene in differ-
ent regulatory mechanisms during the complex signal cascade
leading to luteolysis and ﬁnally to parturition in cattle. Thus, dex-
amethasone imitates the birth-triggering factor cortisol, which is
synthesized by the fetus after maturation of the hypothalamic-
pituitary-axis in late pregnancy [50,51]. This, in turn, stimulates
cotyledonary uninucleate trophoblast cells (UNC) to produce COX2,
which results in upregulation of prostaglandin synthesis [52]. Glu-
cocorticoids are thought to be co-responsible for induction of
CYP17A1 activity in placental cotyledons, thereby participating
in a prepartal switching mechanism redirecting steroid synthe-
sis from delta-4 and delta-5 steroidogenic pathways in favor of
estrogen instead of progesterone synthesis [39,53]. Concomitantly,
sulfonated estrogens may  be activated by increased expression of
estrogen sulphatase [54,55]. Prepartal up-regulation of estrogens
and the simultaneous decrease in progesterone lead to upregula-
tion of PG synthesis, resulting in increased prepartum output of
endometrial and myometrial PGF2 in the cow [56,57].
The competitive P4 receptor blocker aglepristone causes direct
abolition of placental and luteal P4 effects. Cloprostenol, as an
analog of PGF2, simulates the effect of natural endogenous
prostaglandin, which together with oxytocin, stimulates myome-
trial contractility and is directly involved in luteolysis as shown, e.g.,
in cattle and sheep [58,59]. These hormonal changes ﬁnally lead to
the onset of parturition.
Based on the results obtained in the present study, HPGD indeed
seems to participate in these events. Thus, HPGD-speciﬁc mRNA
was detected in all RNA preparations throughout the observa-
tion period and at normal and induced parturition, displaying
time-dependent changes, and indicating its functional role in par-
ticular during the establishment and termination of pregnancy,
when its uterine and placental expression levels, respectively,
were the highest. By revealing the lowest placentomal and uterine
expression levels during the mid-gestation, followed by signiﬁ-
cantly increased mRNA levels in placentomes at parturition, the
expression pattern of HPGD appears to correlate negatively with
the placentomal activity of 3-hydroxysteroid dehydrogenase
(3HSD) and local placentomal concentrations of P4 showed before
[60]. This further implies its functional role during the onset of
parturition.
Similar effects were observed by others in the placenta of
rats which exhibited a decline in placental HPGD activity until
mid-gestation, followed by its increased activity at term [61].
Our ﬁndings showed the clearly detectable immunostaining of
HPGD protein in the fetal compartments of placentomes. In
agreement with other studies in cows and sheep, for exam-
ple [20,62], immunostaining in placentomal trophoblast cells
was generally restricted to the cytoplasm of UNCs, and no
expression was detected in binucleate trophoblast cells (BNC).
The exact role of HPGD in trophoblast cells of the placenta
and fetal membranes is still not clear, however, the co-
localization of HPGD with PG-synthesizing enzymes like COX2 and
20-hydroxysteroid dehydrogenase (20-HSD)/prostaglandin F-
synthase (PGFS/AKR1B5) in the UNCs indicates that PG metabolism
occurs mainly in the fetal components of the placenta [63,64].
With respect to uterine tissues, we  detected immunostaining of
HPGD protein mainly in epithelial cells of the glands and the lumi-
nal epithelium, whereas apparently weaker staining intensity was
detected in cells of maternal stroma and smooth muscles. These
results are equivalent to ﬁndings by other authors who  exam-
ined HPGD expression in the endometrium of cows [65]. This also
suggests that in the bovine uterus and placenta, synthesis and
catabolism of PGs are located in the same cell compartments thus
allowing for efﬁcient regulation of PGs activity in an autocrine
and paracrine manner. In addition, in uterine tissues of different
species like human and cattle, PG-synthesizing-enzymes COX2 and
PGFS/AKR1B5 were predominantly found colocalized with HPGD in
glandular epithelium and maternal stroma [10,16,65,66].
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Fig. 3. Immunolabeling of HPGD protein in bovine placentomes. Representative tissue sections are shown. Clearly visible HPGD staining was found in uninucleate trophoblast
cells  (UNC) and the adherent fetal plate (FP in A). Clearly weaker staining was  observed in the caruncular epithelium (CE). No cytoplasmic staining was detected in binucleate
trophoblast cells (BNC), maternal septum (MS) and fetal stroma (FS). (A) and (D) Group of spontaneously calving cows with discharged fetal membranes (DFM); overview of
the  placentomal villi tree (PVT) is shown in (A). (B) Negative control (isotype control; NC). (C) Group of spontaneously calving cows with retained fetal membranes (RFM).
(E)  Group of cows treated with dexamethasone (GC). (F) Group of cows with aglepristone treatment (AP). (G) Group of cows treated with cloprostenol (CP). (H) Placental
tissue collected in 6th month of gestation.
The increase of placental and uterine HPGD expression around
term may  have a local regulatory function. HPGD not only limits
the levels of each of the major PGs (i.e., PGE2 and PGF2), but also
controls the equilibrium between these two hormones. During par-
turition, the ratio between PGF2 and PGE2 changes [67] and HPGD
could be involved in that mechanism. However, HPGD does not
seem, to be involved in the etiology of fetal membrane retention in
cows, as at least when it comes to its mRNA expression and pro-
tein distribution patterns, they did not differ signiﬁcantly between
retained and normally released placenta.
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Fig. 4. Immunostaining of HPGD protein in bovine uterine tissue during pregnancy. Representative tissue sections are shown. HPGD was mainly detected in the epithelium
(GE,  glandular epithelium) of the uterine glands (UG) and the luminal epithelium (LE). Weaker labeling was observed in the smooth muscle cells and the endometrial stroma
(ES).  MM = myometrium. Immunostaining appeared stronger in the 3rd month (A, B) and weaker in the middle of gestation (C, D).
Furthermore, since uterine PGs are needed locally for the
establishment of pregnancy in different species like cattle, sheep,
pigs and horses [67–72], the elevated expression of HPGD at the
beginning of gestation could be involved in protecting gestation
from PGs entering the maternal blood stream. The myome-
trial expression during that time may  indicate its contribution
to maintaining myometrial quiescence, protecting it from the
contractility-stimulating function of PGs.
The aglepristone and dexamethasone treatments resulted in a
similar decrease of HPGD expression, most probably due to the
withdrawal of P4, since the stimulating effect of progesterone
on HPGD is removed [13,14,23]. Due to the stimulation of HPGD
mRNA expression by progesterone, HPGD was shown to be down-
regulated by PGR blockers like aglepristone and mifepristone in
humans [15,16,73]. Similarly, in the placenta and uterus of guinea
pigs, mifepristone invokes a signiﬁcant decrease of HPGD activ-
ity [74]. Besides being a strong competitive antagonist of PGR,
additionally, mifepristone reveals an afﬁnity for glucocorticoid
receptors [75,76]. The present results provide strong support that
also in cattle the HPGD up-regulating effect of P4 is blocked by
aglepristone.
Cortisol results in a signiﬁcant down-regulation of HPGD and
leads to a potent inhibition of the PGF2 to PGFM conversion in
primary cultures of human placental and chorionic trophoblast
cells [77]. Co-incubation with P4 was not able to reverse the
cortisol-induced inhibition of HPGD activity [77]. However, there is
evidence that regulation of HPGD expression and activity is species-
and cell type- or organ- speciﬁc. Thus, for example, HPGD activity in
fetal rat lung increases after treatment with dexamethasone from
day 20–22 of pregnancy [78], but conversely, renal tissues of rats
show a withdrawal of HPGD activity after dexamethasone treat-
ment [79]. In cattle and humans [14,77], placental glucocorticoids
appear able to block HPGD expression. Our results showed no sig-
niﬁcant differences in mRNA expression of HPGD between cows
medicated with cloprostenol (CP) compared with animals of the
control group (NT). There is evidence, however, that 17- estradiol
increases the activity of HPGD in human placentas [80] and rat uteri
[81,82], and after PGF2-induced luteolysis a switch in the estro-
gen:progesterone ratio in favor of estrogen is observed in cows [20].
This, together with the high prostaglandin concentration, could be
the reason for the high HPGD mRNA expression in the PG group.
Clearly, the presented data obtained in its quantitative part at
the mRNA level, are not deﬁnite. The exact involvement of HPGD in
the endocrine prepartum events in cattle and the underlying mech-
anisms causing the withdrawal of HPGD by glucocorticoids and
aglepristone remain to be further investigated in studies involving
higher number of animals and presenting functional approaches,
including protein expression levels and enzyme activity studies.
5. Conclusions
In bovine placentomes and uterus, HPGD is suggested to play a
regulatory role during establishment and termination of pregnancy
and in protection of the fetus against maternal prostaglandins
and myometrial contractions. Its uterine and placental expres-
sion appears to be time-dependent and, within the placenta, it
is localized predominantly in the fetal part. Thus, its expression
is restricted mainly to the cytoplasm of UNCs, where it seems to
be colocalized with the PG-providing 20-HSD/AKR1B5. At term,
HPGD withdrawal can be induced by aglepristone and the gluco-
corticoid dexamethasone. These data support the assumption that
HPGD is a P4-dependent enzyme.
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